Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) announced the closing of its previously announced non-brokered private placement with Sorbie Bornholm LP and Sorbie Investments LLP, representing a notional subscription amount of approximately CAD$5 million. The financing included the issuance of 7.94 million units at a notional price of CAD$0.63 per unit, with each unit consisting of one common share and one warrant exercisable at CAD$0.77 for three years. The proceeds will be made available to the company through an 18-month sharing arrangement tied to the volume-weighted average trading price of its shares, with monthly settlement amounts varying based on market performance.
Onco-Innovations said it intends to use the net proceeds received under the sharing arrangement to advance development of its ONC010 program, including manufacturing and preclinical activities, support continued development of its SynoGraph platform and provide working capital for general corporate purposes. This capital injection is a significant milestone for the company as it progresses its oncology-focused research and development efforts.
According to the press release, Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. Onco-Innovations has secured an exclusive worldwide license to patented technology that targets solid tumours, positioning it to potentially address significant unmet medical needs in oncology.
The private placement’s structure, involving a sharing arrangement based on trading performance, suggests a strategic approach to funding that aligns investor returns with company performance. This may signal confidence from sophisticated investors like Sorbie Bornholm LP and Sorbie Investments LLP in Onco-Innovations’ prospects.
For more details, the full press release is available at https://ibn.fm/1Hrlg. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.
The implications of this announcement are twofold: it provides Onco-Innovations with the necessary capital to advance its preclinical and manufacturing activities for the ONC010 program and SynoGraph platform, potentially accelerating the timeline for these oncology programs. Additionally, the participation of institutional investors in this private placement may enhance the company’s credibility and visibility in the biotech investment community. As Onco-Innovations moves forward, the successful development of its targeted solid tumour technology could offer new treatment options for cancer patients, making this financing a critical step in its growth trajectory.
